Xtant Medical Appoints Chief Commercial Officer

Xtant Medical Holdings Inc., a developer of regenerative medicine products and medical devices, has appointed Kevin Brandt to the new position of chief commercial officer effective July 9.
 
“We are excited to have such a talented and experienced executive officer join our team,” said Carl O’Connell, CEO of Xtant. “Kevin’s past accomplishments in the medical device industry show that he is an accomplished business strategist with a unique ability to provide the leadership in sales and marketing to build our Company’s revenues and profitability. I expect his contributions will be transformative for Xtant.”
 
Brandt brings to Xtant more than 28 years of experience in the medical device industry. As the former executive vice president and chief commercial officer of RTI Surgical Inc.’s domestic direct business, Brandt led all domestic direct lines of business and R&D for a global surgical implant company marketing biologic, medical and synthetic implants. Prior to joining RTI Surgical in 2012, Brandt spent 18 years at Stryker Corp. from 1994 to 2012 in various senior commercial leadership positions. Most notably, while at Stryker he served as president of Osteokinetics from 2002 to 2012 as one of their largest distributors and prior to that he was senior director of U.S. spine sales from 2000-2001 responsible for creating and leading Stryker’s U.S. spine sales organization.
 
“I’m thrilled to be joining the Xtant team to lead the development and execution of their commercial strategy,” indicated Brandt. “Xtant’s legacy portfolio of biologics and fixation products provide a great foundation to build upon in the field of regenerative medicine and medical devices”.
 
Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets.